Galmed Pharmaceuticals Announces Breakthrough In Pharmacokinetics of Aramchol Meglumine Oral Formulation#Israel#Liver_Disease#Galmed_Pharmaceuticals#Ramat-Gan#Aramchol_Meglumine
Galmed Pharmaceuticals Announces Breakthrough In Pharmacokinetics of Aramchol Meglumine Oral Formulation
Galmed Pharmaceuticals has announced significant results from a pharmacokinetics study of Aramchol Meglumine, showing a remarkable 500% increase in bioavailability compared to standard formulations.
third-news.com
May 14, 2026 at 11:44 AM
Galmed Pharmaceuticals Announces Breakthrough In Pharmacokinetics of Aramchol Meglumine Oral Formulation#Israel#Liver_Disease#Galmed_Pharmaceuticals#Ramat-Gan#Aramchol_Meglumine
Pre-market Volatility Alert! 📉🚀 (Apr 9, 2026)
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
April 9, 2026 at 1:02 PM
Pre-market Volatility Alert! 📉🚀 (Apr 9, 2026)
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
Big moves this morning as we digest fresh clinical data and earnings beats!
🔥 Top Gainers:
#$GLMD +89% | Breakthrough formulation for Aramchol! 🧠 @GalmedPharma
#$GAME +59% | Post-earnings momentum
#StockMarket #Trading #Premarket #Investing #Alpha
Big step forward! A drug for brain diseases like Parkinson's can now cross the blood-brain barrier (BBB) – a natural shield that usually blocks meds. 98% of drugs can't get past it, so this AI-enabled tech is a gamechanger for how we treat those diseases.
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inh
Galmed Pharmaceuticals, in collaboration with Barcode Nanotech, has announced the development of a new formulation for its SCD1 inhibitor, Aramchol, which can now successfully cross the blood-brain ba
www.prnewswire.com
April 11, 2026 at 8:04 PM
Big step forward! A drug for brain diseases like Parkinson's can now cross the blood-brain barrier (BBB) – a natural shield that usually blocks meds. 98% of drugs can't get past it, so this AI-enabled tech is a gamechanger for how we treat those diseases.
#$GLMD developed a breakthrough brain-penetrating formulation of Aramchol in partnership with Barcode Nanotech, using proprietary lipid nanoparticles to deliver the SCD1 inhibitor across the blood-brain barrier for CNS diseases.
prismmarketview.com/companies/ga...
prismmarketview.com/companies/ga...
Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Ar
prismmarketview.com
April 9, 2026 at 8:44 PM
#$GLMD developed a breakthrough brain-penetrating formulation of Aramchol in partnership with Barcode Nanotech, using proprietary lipid nanoparticles to deliver the SCD1 inhibitor across the blood-brain barrier for CNS diseases.
prismmarketview.com/companies/ga...
prismmarketview.com/companies/ga...
She developed an innovative MALDI-TOF MS cellular assay for drug discovery in NAFLD. Her research has identified drugs such as lanifibranor, aramchol, and pifenidone, that blocked the fibrosis phenotype. This research holds promise for treating NAFLD.
June 8, 2023 at 7:59 PM
She developed an innovative MALDI-TOF MS cellular assay for drug discovery in NAFLD. Her research has identified drugs such as lanifibranor, aramchol, and pifenidone, that blocked the fibrosis phenotype. This research holds promise for treating NAFLD.
$GLMD — Foreign Issuer Report
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
August 17, 2026 at 9:30 PM
$GLMD — Foreign Issuer Report
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
Galmed Pharmaceuticals announced preclinical results showing that Aramchol combined with enzalutamide (XTANDI®) increased cancer cell death by 3-4 times compared to enzalutamide alone in prostate cancer models. This is the first reported data for Aram...
🧵 continued ↓
Galmed Pharmaceuticals Reveals Groundbreaking Findings in Prostate Cancer Treatment Research#Israel#Ramat_Gan#Galmed_Pharmaceuticals#Aramchol#XTANDI
Galmed Pharmaceuticals Reveals Groundbreaking Findings in Prostate Cancer Treatment Research
Galmed Pharmaceuticals has unveiled promising results from its studies on Aramchol, revealing significant enhancements in prostate cancer treatment when combined with Xtandi®.
third-news.com
August 17, 2026 at 1:44 PM
Galmed Pharmaceuticals Reveals Groundbreaking Findings in Prostate Cancer Treatment Research#Israel#Ramat_Gan#Galmed_Pharmaceuticals#Aramchol#XTANDI
Galmed Pharmaceuticals Unveils Revolutionary Drug Delivery System for Parkinson's Disease Treatment#Israel#Parkinson's#Ramat_Gan#Aramchol#Galmed
Galmed Pharmaceuticals Unveils Revolutionary Drug Delivery System for Parkinson's Disease Treatment
Galmed Pharmaceuticals reveals their innovative dispersible film delivery system for Aramchol, targeting Parkinson's disease and enhancing treatment efficacy.
third-news.com
July 28, 2026 at 11:11 AM
Galmed Pharmaceuticals Unveils Revolutionary Drug Delivery System for Parkinson's Disease Treatment#Israel#Parkinson's#Ramat_Gan#Aramchol#Galmed
News; ( NASDAQ: #GLMD ) Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
July 16, 2026 at 4:01 PM
Galmed Develops Innovative LNP Formulation of Aramchol Targeting Heart Diseases#Israel#lipid_nanoparticles#Galmed_Pharmaceuticals#Aramchol#Ramat-Gan
Galmed Develops Innovative LNP Formulation of Aramchol Targeting Heart Diseases
Galmed Pharmaceuticals has partnered with Barcode Nanotech to create a groundbreaking LNP formulation of Aramchol, targeting heart diseases and improving treatment options.
third-news.com
July 16, 2026 at 11:44 AM
Galmed Develops Innovative LNP Formulation of Aramchol Targeting Heart Diseases#Israel#lipid_nanoparticles#Galmed_Pharmaceuticals#Aramchol#Ramat-Gan
GLMD
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
July 16, 2026 at 6:12 PM
GLMD
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
GalmedPharma, with partner Barcode Nanotech, says it has built a lipid-nanoparticle version of its SCD1 inhibitor Aramchol designed to reach the heart instead of the liver.
The target is cardiac fibrosis, a real unmet need with no approved therapy.
prismmarketview.com/galmed-...
#GLMD Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
Galmed's Aramchol Formulation Redirects Drug Toward Heart Tissue
Traditional Aramchol accumulates 80%-90% in the liver; the collaboration's platform screens hundreds of nanoparticle candidates for cardiac delivery.
www.stocktitan.net
July 16, 2026 at 11:30 AM
#GLMD Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
https://www.stocktitan.net/news/GLMD/galmed-announces-the-breakthrough-development-of-novel-lnp-cardiac-ox5tw7yf28j9.html
@HepDART dr. Martins @Allergan summarizes ph3 trials planned in progress #obeticholicacid #cenicriviroc #aramchol #resmetirom #elafibranor #belapectin #galectin #hepdart
December 3, 2024 at 2:45 AM
@HepDART dr. Martins @Allergan summarizes ph3 trials planned in progress #obeticholicacid #cenicriviroc #aramchol #resmetirom #elafibranor #belapectin #galectin #hepdart
$GLMD Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models foxrunner.com?fpr=newsscan...
May 6, 2025 at 1:01 PM
$GLMD Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models foxrunner.com?fpr=newsscan...
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks: Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy TipRanks
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy TipRanks
news.google.com
December 4, 2025 at 2:03 PM
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks: Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy TipRanks
Galmed (NASDAQ: GLMD) gains Korea patent for Aramchol–Rezdiffra MASH combo to 2042 - Stock Titan: Galmed (NASDAQ: GLMD) gains Korea patent for Aramchol–Rezdiffra MASH combo to 2042 Stock Titan
Galmed (NASDAQ: GLMD) gains Korea patent for Aramchol–Rezdiffra MASH combo to 2042 - Stock Titan
Galmed (NASDAQ: GLMD) gains Korea patent for Aramchol–Rezdiffra MASH combo to 2042 Stock Titan
news.google.com
December 4, 2025 at 1:36 PM
Galmed (NASDAQ: GLMD) gains Korea patent for Aramchol–Rezdiffra MASH combo to 2042 - Stock Titan: Galmed (NASDAQ: GLMD) gains Korea patent for Aramchol–Rezdiffra MASH combo to 2042 Stock Titan